RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...
Some results have been hidden because they may be inaccessible to you